Cognition and Behavior

Nucleus Accumbens Microcircuit Underlying D2-MSN-Driven Increase in Motivation

Carina Soares-Cunha,^{1,2} Bárbara Coimbra,^{1,2} Ana Verónica Domingues,^{1,2} Nivaldo Vasconcelos,^{1,2,3} Nuno Sousa,^{1,2} and Ana João Rodrigues^{1,2}

DOI:http://dx.doi.org/10.1523/ENEURO.0386-18.2018

¹Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, 4710-057, Portugal, ²ICVS/3B's–PT Government Associate Laboratory, Braga/Guimarães, 4710-057, Portugal, and ³Departamento de Física, Universidade Federal de Pernambuco, Recife, Pernambuco 50670-901, Brazil

Abstract

The nucleus accumbens (NAc) plays a central role in reinforcement and motivation. Around 95% of the NAc neurons are medium spiny neurons (MSNs), divided into those expressing dopamine receptor D1 (D1R) or dopamine receptor D2 (D2R). Optogenetic activation of D2-MSNs increased motivation, whereas inhibition of these neurons produced the opposite effect. Yet, it is still unclear how activation of D2-MSNs affects other local neurons/interneurons or input terminals and how this contributes for motivation enhancement. To answer this question, in this work we combined optogenetic modulation of D2-MSNs with *in loco* pharmacological delivery of specific neurotransmitter antagonists in rats. First, we showed that optogenetic activation of D2-MSNs increases motivation in a progressive ratio (PR) task. We demonstrated that this behavioral effect relies on cholinergic-dependent modulation of dopaminergic signalling of ventral tegmental area (VTA) terminals, which requires D1R and D2R signalling in the NAc. D2-MSN optogenetic activation decreased ventral pallidum (VP) activity, reducing the inhibitory tone to VTA, leading to increased dopaminergic activity. Importantly, optogenetic activation of D2-MSN terminals in the VP was sufficient to recapitulate the motivation enhancement. In summary, our data suggests that optogenetic stimulation of NAc D2-MSNs indirectly modulates VTA dopaminergic activity, contributing for increased motivation. Moreover, both types of dopamine receptors signalling in the NAc are required in order to produce the positive behavioral effects.

Key words: basal ganglia; medium spiny neurons; motivation; nucleus accumbens; optogenetics; reward

Significance Statement

The nucleus accumbens (NAc) is a key brain region of the reward system and is crucial for motivation. We showed that activation of NAc D2-expressing neurons enhances motivation by modulating ventral tegmental area (VTA) dopaminergic activity via ventral pallidum (VP) inhibition. The behavioral effect was dependent on local cholinergic-dependent dopamine release by VTA terminals that required D1 and D2 dopamine receptors (D1R and D2R, respectively) in the NAc. This study reveals for the first time how D2-MSN stimulation can modulate downstream regions and local microcircuit to increase motivation.

Introduction

Dopaminergic projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) have been classically described as the core of the reward circuit (Wise, 2004).

Received November 15, 2017; accepted February 28, 2018; First published April 19, 2018.

The authors declare no competing financial interests.

Evidence in animal models and humans showed that the motivational aspects of reward processing are greatly mediated by these projections (Wise, 1998; Kelley and Berridge, 2002; Hyman et al., 2006; Bailey et al., 2016).

Author contributions: C.S.-C., N.S., and A.J.R. designed research; C.S.-C., B.C., A.V.D., and N.V. performed research; C.S.-C. analyzed data; C.S.-C. and A.J.R. wrote the paper.

The NAc contains 95% of medium spiny neurons (MSNs), that are typically divided into those that express dopamine receptor D1 (D1R, D1-MSNs), and those that express dopamine receptor D2 (D2R, D2-MSNs). In addition to dopaminergic inputs from the VTA, these MSNs receive dense monosynaptic glutamatergic innervation from the medial prefrontal cortex, hippocampus and amygdala (Haber, 2003). These MSNs project directly to the VTA through the direct pathway, mediated exclusively by D1-MSNs, or indirectly via the ventral pallidum (VP; both D1and D2-MSNs; Lu et al., 1998; Zhou et al., 2003; Kupchik et al., 2015). Additionally, MSNs are known to synapse within each other (Sesack and Pickel, 1990; Dobbs et al., 2016), maintaining GABAergic accumbal activity under a balanced control.

The remaining 5% of NAc neurons are local interneurons, that include large tonically active cholinergic interneurons (CINs), fast spiking (FS) GABAergic interneurons, low-threshold spiking (LTS) interneurons (Soares-Cunha et al., 2016b), as well as less explored subtypes, namely tyrosine hydroxylase interneurons (Ibáñez-Sandoval et al., 2010, 2015) and calretinin interneurons (Tepper and Bolam, 2004). Importantly, both cholinergic and GABAergic interneurons play a crucial role in NAc activity and response to salient stimuli and modulate reward-dependent behaviors (Tepper and Bolam, 2004; Lim et al., 2014).

In the past years, compelling data supported a role for D1-MSNs in positive reinforcement, while D2-MSNs have been mostly associated with aversion. Nonetheless, recent data emerged in opposition to this dichotomy; whereas the division of direct and indirect neurons based on the respective expression of D1R and D2R in dorsal striatum appears to be precise, in the NAc the indirect pathway contains a mixture of D1-MSNs and D2-MSNs (Lobo et al., 2010; Kravitz et al., 2012). This implies that both NAc D1- and D2-MSNs can inhibit or disinhibit thalamic activity, with clear repercussions in behavior. In agree-

C.S.-C. was recipient of the Fundação para a Ciência e Tecnologia (FCT) Fellowship SFRH/BD/51992/2012 and is currently recipient of a post-doctoral fellowship from the Programa de Atividades Conjuntas (PAC), through MED-PERSYST Project POCI-01-0145-FEDER-016428 (supported by the Portugal2020 Programme). B.C. is recipient of a PhD scholarship funded by FCT (SFRH/BD/98675/2013). A.J.R. is a FCT Investigator Fellow (IF/00883/2013). N.V. is a recipient of the CNPQ Grant 249991/2013-6 and the CAPES Grant 88887.131435/2016-00. This work was developed under the scope of the project NORTE-01-0145-FEDER-000013, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER). Part of the work was supported by the Janssen Neuroscience Prize (1st edition) and by the BIAL Grant 30/2016.

Acknowledgements: We thank Karl Deisseroth from Stanford University for providing viral constructs and Rui Costa and Ana Vaz from Champalimaud Foundation and Patrícia Monteiro from University of Minho for providing animals and samples for antibody specificity analysis.

Correspondence should be addressed to Ana João Rodrigues, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal, E-mail: ajrodrigues@med.uminho.pt.

DOI:http://dx.doi.org/10.1523/ENEURO.0386-18.2018

Copyright © 2018 Soares-Cunha et al.

ment with this view, a previous study showed that activation of either NAc D1- or D2-MSNs is sufficient to increase motivation in a progressive ratio (PR) task (Soares-Cunha et al., 2016a). In the same direction, in the ventrolateral striatum, both D1- and D2-MSNs are activated at the trial start cue in the PR test and inhibition of either population immediately after the cue resulted in decreased motivation (Natsubori et al., 2017).

These seminal findings showed that D2-MSNs play a more pro-motivation/reward role than initially anticipated and suggest that the prevailing notion of a functional segregation of MSNs should be reconsidered. Yet, it is still unclear how activation of D2-MSNs affects other local neurons/interneurons and downstream regions and how this contributes for motivation enhancement. Therefore, we combined optogenetic activation of NAc D2-MSNs with *in loco* pharmacological delivery of specific antagonists to identify the contribution of different NAc inputs and neuronal populations for motivational drive.

Materials and Methods

Animals

Male Wistar Han rats (two to three months old at the beginning of the tests) were used. Animals were maintained under standard laboratory conditions: 12/12 h light/dark cycle (lights on from 8 A.M. to 8 P.M.) and room temperature of $21 \pm 1^{\circ}$ C, with relative humidity of 50-60%; rats were individually housed after optical fiber implantation; standard diet (4RF21, Mucedola SRL) and water were given ad libitum, until the beginning of the behavioral experiments, in which animals switched to food restriction to maintain 85% of initial body weight.

Behavioral manipulations occurred during the light period of the light/dark cycle. Health monitoring was performed according to FELASA guidelines (Nicklas et al., 2002). All procedures were conducted in accordance with European Regulations (European Union Directive 2010/ 63/EU). Animal facilities and animals' experimenters were certified by the National regulatory entity, Direção-Geral de Alimentação e Veterinária (DGAV). All protocols were approved by the Ethics Committee of the Life and Health Sciences Research Institute (ICVS) and by DGAV.

Experimental design

Group I of animals ($n_{D2-ChR2} = 10$, $n_{D2-eYFP} = 7$), which received intracranial viral injection and optical fiber placement in the NAc, performed the PR test (described in behavior section" throughout) and were killed 90 min after the beginning of the last PR session for c-fos analysis (Extended Data Fig. 1-1*A*).

Group II of animals ($n_{D2-ChR2} = 8$, $n_{D2-eYFP} = 7$), which received intracranial viral injection and hybrid cannula (optics and fluid) placement in the NAc, performed the PR test (described below) and performed two additional PR sessions with antagonist injections. On day 1, half of the animals received antagonist injection and the other half received vehicle injection. On day 2, animals receiving drug on the first day received vehicle and vice versa. All animals were treated with vehicle and drug. After behavioral performance, all rats were killed, and cannula place-

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

ment and viral expression were confirmed (Extended Data Fig. 1-1*B*).

Group III of animals ($n_{D2-ChR2 NAC-VP} = 8$, $n_{D2-eYFP NAC-VP} = 6$), which received intracranial viral injection in the NAc and optical fiber placement in the VP, performed the PR test (described below; Extended Data Fig. 1-1*C*).

Group IV of animals ($n_{D2-ChR2} = 4$) was injected with ChR2 in the NAc, and after three weeks to allow viral expression, *in vivo* single unit electrophysiological recordings were performed (Extended Data Fig. 1-1*D*).

Behavior

Subjects and apparatus

Rats were habituated to 45 mg of food pellets (F0021; Bio-Serv), which were used as reward during the behavioral protocol, 1 d before training initiation. Behavioral sessions were performed in operant chambers (Med Associates) that contained a central, recessed magazine to provide access to 45 mg of food pellets (Bio-Serve), two retractable levers with cue lights located above them that were located on each side of the magazine. Chamber illumination was obtained through a 2.8-W, 100-mA light positioned at the top-center of the wall opposite to the magazine. The chambers were controlled by a computer equipped with the Med-PC software (Med Associates).

PR schedule of reinforcement

All training sessions started with illumination of the house light that remained until the end of the session. On the first training session [continuous reinforcement (CRF) sessions] one lever was extended. The lever would remain extended throughout the session, and a single lever press would deliver a food pellet (maximum of 50 pellets earned within 30 min). In some cases, food pellets were placed on the lever to promote lever pressing. After successful completion of the CRF training, rats were trained to lever press on the opposite lever using the same training procedure. In the four following days, the side of the active lever was alternated between sessions. Then, rats were trained to lever press one time for a single food pellet in a fixed ratio (FR) schedule consisting in 50 trials in which both levers are presented, but the active lever is signaled by the illumination of the cue light above it. FR sessions began with extension of both levers (active and inactive) and illumination of the house light and the cue light over the active lever. Completion of the correct number of lever press led to a pellet delivery, retraction of the levers and the cue light turning off for a 20-s intertrial interval (ITI). Rats were trained first with one lever active and then with the opposite lever active in separate sessions (in the same day). In a similar manner, rats were then trained using an FR4 reinforcement schedule for 4 d and a FR8 for 1 d. On the test day, rats were exposed to PR or FR experimental sessions (one session per day) according to the following schedule: day 1, FR4; day 2, PR (optical stimulation); day 3, FR4; day 4, PR (no optical stimulation). PR sessions were identical to FR4 sessions except that the operant requirement on each trial (T) was the integer (rounded down) of 1.4^(T-1) lever presses, starting at 1 lever press. PR sessions ended after 15 min elapsed without completion of the response requirement in a trial.

Before the PR session, rats were connected to an opaque optical fiber, through previously implanted cannula guide placed in the NAc. At the beginning of each trial of the PR session with optical stimulation, when the retractable levers are exposed to the animal together with the cue light, animals received an optical stimulation. After basal assessment of PR (one session with optical stimulation and one session without), all animals performed seven additional sessions (with one-week interval and one FR4 reminder session before PR test) with optical stimulation and local pharmacological administration of receptors antagonist (Extended Data Fig. 1-1).

Optical stimulation was performed as follows: 473 nm; frequency of 40 Hz; 12.5-ms pulses over 1 s; 10 mW at the tip of the implanted fiber.

Constructs and virus preparation

eYFP or hChR2(H134R)-eYFP were cloned under the control of the D2R minimal promoter region as described before (Soares-Cunha et al., 2016a; Zalocusky et al., 2016). Constructs were packaged in AAV5 serotype by the University of North Carolina at Chapel Hill (UNC) Gene Therapy Center Vector Core (UNC). AAV5 vector titters were $3.7-6 \times 10^{12}$ viral molecules/ml as determined by dot blot.

Surgery and cannula implantation

Rats were anesthetized with 75 mg kg⁻¹ ketamine (Imalgene, Merial) plus 0.5 mg kg⁻¹ medetomidine (Dorbene, Cymedica). Virus was unilaterally injected into the NAc; coordinates from bregma, according to (Paxinos and Watson, 2005): +1.2 mm anteroposterior (AP), +1.2 mm mediolateral (ML), and -6.5 mm dorsoventral (DV; D2-ChR2 group and D2-eYFP control group). Rats that performed the PR with only optical stimulation were implanted with an optic fiber (200 μ m in diameter) attached to a 2.5-mm ferrule (Thorlabs), and rats that performed the PR test with both optical stimulation and local administration of antagonists were implanted with opto-fluid cannulas (Doric Lenses) using the injection coordinates (except for the DV: -6.4 mm) that were secured to the skull using 2.4-mm screws (Bilaney) and dental cement (C&B kit, Sun Medical).

For NAc terminal stimulation in the VP, virus was injected as above but rats were implanted with an optic fiber in the VP (coordinates from bregma) -0.1 mm AP, +2.4 mm ML, and -7 mm DV (D2-ChR2 NAc-VP group and D2-eYFP NAc-VP control group).

Rats were allowed to recover for two weeks before initiation of the behavioral trainings.

In vivo single-cell electrophysiology

Three weeks postsurgery, D2-ChR2 rats (n = 4) were anaesthetized with urethane (1.44 g kg⁻¹, Sigma). The total dose was administered in three separate intraperitoneal injections, 15 min apart. Adequate anesthesia was confirmed by the lack of withdrawal responses to hindlimb pinching. A recording electrode coupled with a fiber optic patch cable (Thorlabs) was placed in the NAc (coordinates from bregma: +1.2 mm AP, +1.2 mm ML, and -6.0 to -7.0 mm DV), using a stereotaxic frame (David Kopf Instruments) with nontraumatic ear bars (Stoeling). Other recording electrodes with fiber optic attached were placed in the VP (coordinates from bregma: 0 to -0.12 mm AP,

+2.3 to +2.5 mm ML, and -7 to -7.6 mm DV) and in the VTA (coordinates from bregma: -5.3 mm AP, +0.9 mm ML, and -7.5 to -8.3 mm DV).

Single neuron activity was recorded extracellularly with a tungsten electrode (tip impedance 5–10 Mat 1 kHz) and data sampling was performed using a CED Micro1401 interface and Spike2 software (Cambridge Electronic Design). The DPSS 473 nm laser system, controlled by a stimulator (Master-8, AMPI) was used for intracranial light delivery. Optical stimulation was performed as follows: 473 nm; frequency of 40 Hz; 12.5-ms pulses over 1 s, 10 mW.

Firing rate histograms were calculated for the baseline (10 s before stimulation), stimulation period and after stimulation period (10 s after the end of stimulation). Spike latency was determined by measuring the time between half-peak amplitude for the falling and rising edges of the unfiltered extracellular spike.

NAc neurons were classified according to previous descriptions (Jin et al., 2014; Vicente et al., 2016). In short, fast-spiking interneurons (FSIs), putative parvalbumincontaining neurons (pFSs), were identified has having a waveform half-width of less that 100 μ s and a baseline firing rate higher that 10 Hz; tonically active putative CINs (pCINs) were identified as those with a wave form half-width bigger that 300 μ s. Putative MSNs (pMSNs) were identified as those with baseline firing rate lower that 5 Hz and that do not met the wave form criteria for pCIN or pFS neurons.

VP GABAergic neurons were identified as those having a baseline firing rate between 0.2 and 18.7 Hz (Richard et al., 2016). Other nonidentified neurons (corresponding to less that 5% of recorded cells) were excluded from the analysis.

Single units in the VTA were separated into those putative dopaminergic (pDAergic) and putative GABAergic (pGABAergic). This classification was based on firing rate and wave form duration (Ungless et al., 2004; Ungless and Grace, 2012; Totah et al., 2013). Cells presenting baseline firing rate lower that 10 Hz and a wave form duration higher than 1.5 ms were considered pDAergic neurons. Cells presenting baseline firing rate higher than 10 Hz and wave form duration lower than 1.5 ms were classified as pGABAergic. Other single units that did not fit in any classification (<5% of recorded cells) were excluded from the analysis.

Immunofluorescence (IF)

Ninety minutes after initiation of the PR test, rats were deeply anesthetized with pentobarbital (Eutasil) and were transcardially perfused with 0.9% saline followed by 4% paraformaldehyde. Brains were removed and postfixed in 4% paraformaldehyde. Coronal vibratome sections (50 μ m) were incubated with mouse anti-D2R (1:500, catalog #sc-5303, RRID: AB_668816, Santa Cruz Biotechnology), rabbit anti-c-fos (1:1000, Merck Millipore catalog #Ab-5, RRID: AB_2314042), goat or mouse anti-GFP (1:500, Ab-cam catalog #ab6673, RRID: AB_305643; or Abcam catalog #ab1218, RRID: AB_298911), mouse anti-D1R (1: 100, Novus catalog #NB110-60017, RRID: AB_905382), and goat anti-ChAT (1:750, Millipore catalog #AB144P,

RRID: AB_2079751). Appropriate secondary fluorescent antibodies were used (1:500, Invitrogen; catalog #A-21206, RRID:AB_141708; catalog #R37119, RRID:AB_2556547; catalog #A-21202, RRID:AB_141607; catalog #R37114, RRID: AB_2556542; catalog #A-11055, RRID:AB_142672). Finally, all sections were stained with 4',6-diamidino-2-phenylindole (DAPI; 1 mg ml⁻¹). Anti-D1R and anti-D2R antibodies were previously validated (Luedtke et al., 1999; Basu et al., 2004; Luessen et al., 2016; Extended Data Fig. 5-1).

For each brain region, countings were performed in five distinct $50-\mu m$ sections. Images were collected and analyzed by confocal microscopy (Olympus FluoViewT-MFV1000). Cell counts were normalized to the area of the brain region.

Drugs

All drugs were delivered 10 min before animals performed the PR test, through an opto-fluid system chronically implanted in the NAc. Injections were performed using a 5- μ l gastight seringe (Hamilton), attached to the implanted injection cannula of the rats through 22-gauge tubing, at a constant rate of 1 μ l/min.

The drugs used in experimental procedures were: R(+)-SCH-23390 hydrochloride (D1R antagonist, 0.25 μ g in 0.5 μ l of saline, Sigma); (S)-(-)-sulpiride (D2R antagonist, 0.2 μ g in 1 μ l, Sigma); scopolamine hydrobromide [muscarinic acetylcholine receptor (mAChR) antagonist, 25 μ g in 1 μ l, Sigma]; mecamylamine hydrochloride (nAChR antagonist, 22.5 μ g in 1 μ l, Sigma); Ddihydro- β -erythroidine hydrobromide (DH β E, α 4-nAChR antagonist, 0.7 μ g in 1 μ l, Tocris); CGP-55845 hydrochloride (GABA(B) receptor antagonist, 44 ng in 0.5 μ l, Sigma); 1(S),9(R)-(-)-bicuculine methobromide (GABA(A) receptor antagonist, 75 ng in 0.5 μ l, Sigma).

Statistical analysis

Normality tests were performed for all data analyzed, as well as outlier analysis using Tukey's test. Statistical analysis between two groups was made using two-tailed Student's *t* test (unpaired *t* test for comparison between two groups; paired *t* test for comparison within the same group). One- or two-way ANOVA was used when appropriate. Bonferroni's *post hoc* multiple comparisons were used for group differences determination. Statistical results are displayed in Table 1. Results are presented as mean \pm SEM. All statistical analysis was performed using GraphPad Prism (v7.0), and results were considered significant for $p \leq 0.05$.

Results

Optogenetic stimulation of NAc D2-MSNs increases motivation

To specifically modulate the activity of NAc D2R-expressing neurons, we injected in the NAc of rats a construct containing channelrhodopsin (ChR2) in fusion with enhanced yellow fluorescent protein (eYFP) under the control of the D2R minimal promoter (pAAV-D2Rp-hChR2(H134R)eYFP), or the control eYFP virus (pAAV-D2Rp-eYFP; Fig. 1*A*,*B*; Extended Data Fig. 1-2; Soares-Cunha et al.,

Table 1. Statistical table

Figure	Data structure	Sample size	Type of test	Statistics
1 <i>F</i>	Normal distribution	23 cells from four rats	One-way ANOVA	$F_{(2,48)} = 74.7, p < 0.000$
1 <i>H</i>	Normal distribution	$n_{\text{DO}} = 7$	Two-way ANOVA	$F_{(4,40)} = 0.43 \ p = 0.322$
		$n_{-2} = 10$		(1,13) 0110, p 01022
11	Normal distribution	$n_{D2-ChR2} = 10$		F = -104.9 m < 0.000
17	Normal distribution	$\Pi_{D2-eYFP} = 7,$	Two-way ANOVA	$r_{(3,30)} = 124.6, p < 0.000$
		$n_{D2-ChR2} = 10$		
1 <i>J</i>	Normal distribution	$n_{D2-eYFP} = 7;$	Unpaired <i>t</i> test, two tailed	$t_{(13)} = 7.7, p < 0.000$
		$n_{D2-ChR2} = 10$		
1 <i>K</i>	Normal distribution	$n_{D2-eYEP} = 7;$	Two-way ANOVA	Laser effect: $F_{(1,13)} = 47.3, p < 0.000$
		$n_{\text{D2-ChD2}} = 10$	2	Group effect: $F_{(1,12)} = 7.9$, $p < 0.000$
		D2-GINZ		Bonferroni post test: D2-ChB2 ON vs D2-ChB2 OFF
11	Normal distribution	n – 7.	I provided the totat two toiled	p < 0.001
1L	Normal distribution	$\Pi_{D2-eYFP} = 7,$	Unpaired i test, two tailed	$l_{(13)} = 1.3, p = 0.1360$
		$n_{D2-ChR2} = 10$		
1 <i>M</i>	Normal distribution	$n_{D2-eYFP} = 7;$	Unpaired t test, two tailed	$t_{(13)} = 0.7, p = 0.4719$
		$n_{D2-ChB2} = 10$		
1 <i>N</i>	Normal distribution	$n_{D2-eYEP} = 7;$	Unpaired t test, two tailed	$t_{(13)} = 1.0, p = 0.3124$
		$n_{P2} + n_{P2} = 10$	•	(10)
2B	Normal distribution	$n_{-1} = -1 = 7$		Treatment effect: $E_{n,m} = 0.1$, $p = 0.117$
20	Normal distribution	-7	Two way ANOVA	Group effect: $F_{(1,13)} = 0.1, p = 0.117$
		IID2-eYFP GABAA antag — 7,		Group effect: $F_{(1,13)} = 110.0, p < 0.000$
		$n_{D2-ChR2 veh} = 8;$		Bonterroni post test:
		$n_{D2-ChR2 \text{ GABAA antag}} = 8$		D2-ChR2 vehicle vs D2-ChR2 GABA(A) antag: $p = 0.787$
2C	Normal distribution	$n_{D2-eYFP veh} = 7;$	Two-way ANOVA	Treatment effect: $F_{(1,13)} = 30.7$, $\rho < 0.000$
		$n_{D2-eYFP GABAB antag} = 7;$		Group effect: $F_{(1,13)} = 193$, $p < 0.000$
		$n_{D2-CbB2} = 8;$		Bonferroni post test:
		$n_{\text{DB}} \sim n_{\text{B}} \sim n_{\text{B}} \sim n_{\text{B}} = 8$		D2-eYFP vehicle vs D2-eYFP GABA(B) antag: $\rho = 0.07$
		···D2-CITH2 GABAB arriag		D2-ChB2 vehicle vs D2-ChB2 GABA(B) antag: $p < 0.000$
20	Normal distribution	n – 7.		Treatment effects $\Gamma_{-} = 4.2$, $n = 0.001$
20	Normal distribution	$\Pi_{D2-eYFP veh} = 7$,	Two-way ANOVA	Derfement effect. $P_{(3,39)} = 4.3$, $p = 0.001$
		$\Pi_{D2-eYFP}$ mAChR+nAChR antag = T ;		Bonterroni post test:
		n _{D2-eYFP mAChR antag} = 7;		D2-ChR2 vehicle vs D2-ChR2 mAChR+nAChR antag: $p < 0.000$
		$n_{D2-eYFP nAChR antag} = 7;$		D2-ChR2 vehicle vs D2-ChR2 nAChR antag: $ ho < 0.000$
		$n_{D2-ChR2 veh} = 8;$		
		$n_{D2-ChB2} = 8;$		
		n_{DB} chas matched enter = 8:		
		$n_{\text{D2-OHR2}}$ machine antag $= 8$		
0E	Normal distribution	- T- T-		Treatment effect: $E_{n} = 42.0 \text{ p} < 0.000$
26	Normal distribution	ID2-eYFP veh = 7,	Two-way ANOVA	Perference electr $r_{(1,13)} = 43.0, p < 0.000$
		$n_{D2-eYFP \alpha 4*-nAChR antag} = 7;$		Bonferroni post test:
		$n_{D2-ChR2 veh} = 8;$		D2-ChR2 vehicle vs D2-ChR2 α 4 antag: $p < 0.000$
		$n_{D2-ChR2 \alpha 4*-nAChR antag} = 8$		
2F	Normal distribution	$n_{D2-eYFP veh} = 7;$	Two-way ANOVA	Treatment effect: D1R antag: $F_{(1,13)} = 43.7, p < 0.000$
		$n_{D2-eYEP D1B antag} = 7;$		Bonferroni post test:
		$n_{D2-CbB2} = 8;$		D2-eYFP vehicle vs D2-eYFP D1R antag: $p = 0.047$
		$n_{\text{D2}} + n_{\text{D2}} + n_{\text{D2}} = 8$		D2-ChB2 vehicle vs D2-ChB2 D1B antag: $p < 0.000$
2G	Normal distribution	$n_{\text{powners}} = 7$	Two-way ANOVA	Treatment effect: D2B antag: E_{μ} in = 34.8 $p < 0.000$
20	Normal distribution	-7		Performing post test:
		IID2-eYFP D2R antag - 7,		Domenoni post test.
		$n_{D2-ChR2 veh} = 8;$		D2-eYFP venicie vs D2-eYFP D2R antag: $p = 0.013$
		$n_{D2-ChR2 D2R antag} = 8$		D2-ChR2 vehicle vs D2-ChR2 D2R antag: $p < 0.000$
3B	Normal distribution	$n_{D2-ChR2} = 8;$	Unpaired t test, two tailed	D2-ChR2 vs D2-eYFP rats: t ₍₁₃₎ = 12.0, p < 0.000
		$n_{D2-eYFP} = 7$		
3B	Normal distribution	$n_{D2-CbB2} = 8$	Paired t test, two tailed	Stimulated vs contralateral side: $t_{(7)} = 7.4$, $p = 0.0002$
3C	Normal distribution	$n_{\text{DD}} = 8$	Unpaired <i>t</i> test two tailed	D2-ChB2 vs D2-eYEP rats: $t_{exp} = 3.7$ $p = 0.0028$
		$n_{-2} = 7$		
20	Normal distribution	nD2-eYFP - 7	Daired t test two tailed	Stimulated value controlatoral side: $t = 2.2$, $p = 0.0011$
30		$\Pi_{D2-ChR2} = 0$		Sumulated vs contralateral side. $t_{(7)} = 3.5$, $p = 0.0011$
3D	Normal distribution	$n_{D2-ChR2} = 8;$	Unpaired t test, two tailed	D2-ChR2 vs D2-eYFP rats: $t_{(13)} = 3.7$, $p < 0.000$
		$n_{D2-eYFP} = 7$		
3D	Normal distribution	$n_{D2-ChB2} = 8$	Paired t test, two tailed	Stimulated vs contralateral side: $t_{(7)} = 4.0, p = 0.0033$
3F	Normal distribution	$n_{D2,ChB2} = 8$:	Unpaired t test, two tailed	D2-ChR2 vs D2-eYFP rats: $t_{(12)} = 3.3$, $p < 0.000$
		$n_{\text{DO}} = 7$		(13)
3E	Normal distribution	n – 8	Paired t test two tailed	Stimulated vs contralateral side: $t = 4.4$ p = 0.0024
00		IID2-ChR2 0		Sumulated vs contralateral side. $r_{(7)} = 4.4, p = 0.0024$
3G	Normal distribution	$n_{D2-ChR2} = 8;$	Unpaired t test, two tailed	D2-ORZ VS D2-eYFP rats: $t_{(13)} = 0.3, p = 0.418$
		$n_{D2-eYFP} = 7$		
3G	Normal distribution	$n_{D2-ChR2} = 8$	Paired t test, two tailed	Stimulated vs contralateral side: $t_{(7)} = 0.1$, $p = 0.9099$
3/	Normal distribution	$n_{D2-ChB2} = 8;$	Unpaired t test, two tailed	D2-ChR2 vs D2-eYFP rats: $t_{(13)} = 2.3, p = 0.039$
		$n_{D2-eVEP} = 7$		(,
3/	Normal distribution	$n_{\text{DD}} = 8$	Paired t test two tailed	Stimulated vs contralateral side:
		···D2-ChR2		t = 1.2 n = 0.238
40	NUMBER OF STREET		0	$r_{(7)} = 1.2, \mu = 0.230$
4 B	Normal distribution	30 cells from four rats	One-way ANOVA	$F_{(2,87)} = 10.4, p < 0.000$
4 <i>E</i>	Normal distribution	29 pDAergic cells from four rats;	One-way ANOVA	pDAergic: F _(2,34) = 17.4, p < 0.000
		three pGABAergic cells from four rats		pGABAergic: $F_{(2.8)} = 2.7, p = 0.1343$
4/	Normal distribution	$n_{D2-CbB2} = 8, n_{D2-CVED} = 4$	Unpaired t test, two tailed	$t_{(11)} = 10.7, p < 0.000$
4./	Normal distribution	$n_{\text{DD}} = 8$	Paired t test two tailed	$t_{(n)} = 10.2, p < 0.000$
1K	Normal distribution	n - 9 n - 4	Innaired t test, two tailed	t = 1.7 p = 0.112
-+/ \		$^{\prime\prime}D2-ChR2 NAc-VP = 0, ^{\prime\prime}D2-eYFP NAc-VP = 4$		(12) - 1.7, p = 0.112
			(Continued)	

Table 1. Continued

Figure	Data structure	Sample size	Type of test	Statistics
2-2A	Normal distribution	$n_{D2-eYFP veh} = 7;$	Two-way ANOVA	Bonferroni post test:
		$n_{D2-eYFP \text{ GABAA antag}} = 7;$		D2-eYFP vehicle vs D2-eYFP antag: $p = 0.4831$
		$n_{D2-ChR2 veh} = 8;$		D2-ChR2 vehicle vs D2-ChR2 antag: $\rho = 0.7434$
		n _{D2-ChR2} GABAA antag = 8		
2-2B	Normal distribution	$n_{D2-eYFP veh} = 7;$	Two-way ANOVA	Bonferroni post test: D2-eYFP vehicle vs D2-eYFP antag: $p = 0.7334$
		$n_{D2-eYFP \text{ GABAB antag}} = 7;$		
		$n_{D2-ChR2 veh} = 8;$		D2-ChR2 vehicle vs D2-ChR2 antag: $p = 0.9332$
		n _{D2-ChR2} GABAB antag = 8		
2-2C	Normal distribution	$n_{D2-eYFP veh} = 7;$	Two-way ANOVA	Bonferroni post test:
		n _{D2-eYFP} mAChR+nAChR antag = 7;		D2-eYFP vehicle vs D2-eYFP mAChR+nAChR antag: $p = 0.9994$
		n _{D2-eYFP mAChR antag} = 7;		D2-ChR2 vehicle vs D2-ChR2 mAChR+nAChR antag: $p = 0.9883$
		n _{D2-eYFP nAChR antag} = 7;		D2-eYFP vehicle vs D2-eYFP mAChR antag: $p = 0.9994$
		$n_{D2-ChR2 veh} = 8;$		D2-ChR2 vehicle vs D2-ChR2 mAChR antag: $p = 0.9883$
		n _{D2-ChR2} mAChR+nAChR antag = 8;		D2-eYFP vehicle vs D2-eYFP nAChR antag: $p = 0.4483$
		$n_{D2-ChR2 mAChR antag} = 8;$		D2-ChR2 vehicle vs D2-ChR2 nAChR antag: $p = 0.9187$
		$n_{D2-ChR2 nAChR antag} = 8$		- - - - - - - - - -
2-2D	Normal distribution	$n_{D2-eYFP veh} = 7;$	Two-way ANOVA	Bonferroni post test:
		$n_{D2-eYFP \alpha 4*-nAChR antag} = 7;$		D2-eYFP vehicle vs D2-eYFP antag: $p = 0.4489$
		$n_{D2-ChR2 veh} = 8;$		D2-GHR2 vehicle vs D2-GHR2 antag: $p = 0.7023$
0.05	NUMBER OF STREET	$n_{D2-ChR2 \alpha 4*-nAChR antag} = 8$	T	Destruction of test
2-2E	Normal distribution	$n_{D2-eYFP veh} = 7;$	Two-way ANOVA	Bonterroni post test:
		$n_{D2-eYFP D1R antag} = T;$		D2-eYFP vehicle vs D2-eYFP antag: $p = 0.0144$
		$n_{D2-ChR2 veh} = 8;$		D2-GRZ vehicle vs D2-GRZ antag: $p = 0.0842$
0.0E	Normal distribution	$II_{D2-ChR2} D1R antag = 0$		Ponforrani post tost:
2-21-	Normal distribution	$II_{D2-eYFP veh} = 7$,	Two-way ANOVA	D0 aVEP vahiale va D2 aVEP antag: $p = 0.0000$
		IID2-eYFP D2R antag - 7,		D2-eTFF vehicle vs D2-eTFF alray. $p = 0.3333$
		$I_{D2-ChR2 veh} - 6,$		D2-OTHZ VEHICLE VS D2-OTHZ antag. $p = 0.2506$
1-1R	Normal distribution	D2-ChR2 D2R antag - 0		Group effect: $E_{1} = 0.0$ p = 0.856
4 10	Normal distribution	D2-ChR2 NAc-VP - 0, IID2-eYFP NAc-VP - 0	Two way ANOVA	Dry of training effect: $F_{(1,72)} = 0.0, p = 0.050$
4-10	Normal distribution	11D2-ChR2 NAC-VP - 0, 11D2-eYFP NAC-VP - 0	I WO-Way ANOVA	Day of training effect. $r_{(3,24)} = 130.4, p < 0.000$

2016a; Zalocusky et al., 2016). Nearly 60% of NAc D2Rexpressing neurons were successfully transfected with ChR2 or eYFP (D2R⁺/eYFP⁺ cells; Fig. 1*C*). In addition, only 1.5% of eYFP⁺ cells were D1R⁺; and 2% were ChAT⁺. Forty % of ChAT⁺ cells (CINs) were transfected since they express eYFP (Extended Data Fig. 1-2).

Using single-cell *in vivo* electrophysiology, we showed that D2-MSN optical stimulation (40 Hz, 40 light pulses at 12.5 ms) significantly increases NAc firing rate during stimulation in comparison with baseline, and 84% of the cells return to basal activity after stimulation ($F_{(2,48)} =$ 76.7, p < 0.000, one-way ANOVA; Fig. 1*D*–*F*). A total of 68% of recorded cells increased activity, 16% decrease, and 24% did not change activity in response to stimulation. Spike latency was ~2 ms (Fig. 1*G*).

After, animals were submitted to PR test (Extended Data Fig. 1-1) to evaluate their willingness to work for a food reward, a direct measure of individual motivation. During CRF training, both groups increased lever pressing throughout days in a similar manner ($F_{(1,15)} = 0.43$, p = 0.522, two-way ANOVA; Fig. 1*H*). Likewise, all animals increased lever pressing in the FR schedule days in the active versus nonactive lever ($F_{(3,30)} = 126.8$, p < 0.000, two-way ANOVA; Fig. 1*I*).

In agreement with previous findings (Soares-Cunha et al., 2016a), D2-MSNs optical stimulation (40 light pulses of 12.5 ms at 40 Hz) occurring at the same time as the conditioned stimulus (light above the active lever), induced a significant increase in the breakpoint of D2-ChR2 rats in comparison with D2-eYFP-stimulated rats (63.6% increase; $t_{(15)} = 7.7$, p < 0.000, unpaired *t* test; Fig. 1*J*). All D2-ChR2 rats displayed a significant increase in the breakpoint in the session with optical stimulation (ON) in comparison with the session without stimulation

(OFF; two-way ANOVA *post hoc*, p < 0.000; Fig. 1*K*). This increase in motivation was not due to differences in the number of food pellets earned during the PR session $(t_{(15)} = 1.5, p = 0.1380, \text{ unpaired } t \text{ test}; \text{ Fig. 1L})$. Stimulation occurring during the ITI had no effect on motivation (Fig. 1*M*,*N*), proving that the positive effect of stimulation in behavior was restricted to particular stages of the test.

Increase in motivation is dependent on NAc GABA signaling

MSNs are GABAergic in nature and synapse within each other in the NAc (Dobbs et al., 2016). Besides, local interneurons provide an additional source of GABA that also controls MSNs activity (Fig. 2A; Tepper et al., 2004).

To further understand the impact of GABAergic neurotransmission in the control of D2-MSNs-mediated enhancement of motivation, we used hybrid cannulas, which allow dual delivery of drugs and light in the same region (Extended Data Figs. 1-1, 2-1). Immediately before behavioral testing and optogenetic activation of D2-MSNs, we injected in the NAc either a GABA_A receptor antagonist (bicuculline, 75 ng) or a GABA_B receptor antagonist (CGP 55845 hydrochloride, 44 ng), in dosages that have been shown previously to induce a behavioral effect (Giorgetti et al., 2002; Kandov et al., 2006; Ikeda et al., 2010).

For GABA_A receptor antagonist, we found no significant effect of treatment but there was a group effect, with D2-ChR2-stimulated animals presenting increased breakpoint (two-way ANOVA; treatment effect: $F_{(1,13)} = 0.1, p = 0.117$; group effect: $F_{(1,13)} = 118.8, p < 0.000$; Fig. 2*B*). For GABA_B receptor antagonist, there was a significant effect of treatment and group (two-way ANOVA; treatment effect: $F_{(1,13)} = 30.7, p < 0.000$; group effect: $F_{(1,13)} = 193, p < 0.000$; Fig. 2*C*).



Figure 1. Optical stimulation of NAc D2-MSNs increases motivation. *A*, AAV5-D2-ChR2(H134R)-eYFP (D2-ChR2 group) or AAV5-D2-eYFP (D2-eYFP group) was unilaterally injected in the NAc of Wistar han rats. A hybrid cannula was placed in the NAc to allow simultaneous delivery of fluids and optical stimulation. *B*, Expression of eYFP was confirmed by YFP immunostaining. Scale bar: 500 μ m; numbers represent distance to bregma in millimeters. *C*, Representative immunostaining for D2R and eYFP in the NAc of an animal injected with AAV5-D2-ChR2(H134R)-eYFP. Scale bar: 100 μ m, inset scale bar: 50 μ m. More than 50% of D2-MSNs were transfected (*n* = 6 animals/group). *D*, On D2-MSN optical stimulation (12.5-ms light pulses at 40 Hz, during 1 s), 60% of cells increased activity, 16% decreased, and 24% did not respond in comparison with baseline (*n* = 25 cells from four rats). *E*, Time histogram of NAc electrophysiological single units in response to optical stimulus (average of 25 cells; blue stripe corresponds to laser

continued

stimulation). **E'**, Example of a ChR2 neuron that responds to each pulse of stimulation. Right, Example of a representative MSNs wave form. **F**, Increase in NAc average firing rate during optogenetic stimulation of D2-MSNs. **G**, Spike latency in response to D2-MSN optical stimulation. **H**, CRF training sessions of the PR test. **I**, FR training sessions of the PR test. **J**, Optogenetic activation of D2-MSNs during cue exposure strongly enhanced breakpoint. **K**, All animals increase breakpoint in the session with D2-MSN stimulation (ON versus OFF session). **L**, Number of pellets consumed in the PR session with stimulation was similar between groups. **M**, Optogenetic activation of D2-MSNs during ITI does not alter breakpoint. **N**, Number of pellets earned in the PR session with stimulation on ITI was similar between groups. $n_{D2-eYFP} = 7$; $n_{D2-ChR2} = 10$. Error bars denote SEM; ***p < 0.001 (Extended Data Figs. 1-1, 1-2).

None of the GABA antagonists alters the breakpoint of control D2-eYFP animals (Fig. 2*B*,*C*), although there was a trend for increased number of lever presses with GABA_B receptor antagonist treatment (12% increase; *p* = 0.070, two-way ANOVA *post hoc*). GABA_A receptor antagonist administration before D2-MSNs stimulation did not impair the breakpoint enhancement (D2-ChR2 vehicle vs D2-ChR2 GABA_A antag, *p* = 0.787, two-way ANOVA *post hoc*; Fig. 2*B*). However, administration of GABA_B receptor antagonist led to an additional increase in the breakpoint of D2-stimulated animals (15.8% increase; *p* < 0.000, two-way ANOVA *post hoc*; Fig. 2*C*). No differences were found between groups in the number of pellets earned during the session (Extended Data Fig. 2-2).

These results suggest that GABA signaling arising from MSNs or local interneurons can modulate motivational drive in a GABA_B-dependent manner.

Increase in motivation is dependent on NAc cholinergic signaling

In addition to GABAergic modulation, MSNs activity is tightly controlled by CINs (Fig. 2*A*), which are able to control dopamine release from VTA terminals in the NAc (Cachope et al., 2012), promoting behavioral conditioning (Witten et al., 2010).

Using a similar approach as above, we injected in the NAc a combination of mAChR and nicotinic AChR (nAChR) antagonists before PR paradigm (scopolamine, 25 μ g; mecamylamine, 22.5 μ g, respectively; dosages previously validated; Nadal et al., 2002; Rahman and McBride, 2002; Yee et al., 2011; Perry et al., 2014). Treatment had a significant effect on behavior ($F_{(3,39)} = 6.3$, p = 0.001, two-way ANOVA; Fig. 2D). Blockade of cholinergic signaling significantly abolished the motivation enhancement induced by optogenetic D2-MSN activation (D2-ChR2 vehicle vs D2-ChR2 mAChR + nAChR antag, p < 0.000, two-way ANOVA *post hoc*; Fig. 2D).

Further studies using either one of the antagonists revealed that this blockage was mediated by nAChR (D2-ChR2 vehicle vs D2-ChR2 nAChR antag, two-way ANOVA *post hoc*, p < 0.000; Fig. 2D). No differences in the number of pellets earned during the session were found (Extended Data Fig. 2-2).

In the NAc, MSNs express mAChR (M1 and M4; Yan et al., 2001) but not nAChR (Jones et al., 2001; Jones and Wonnacott, 2004). The later receptors are mainly expressed in VTA dopaminergic terminals (Hill et al., 1993) and some GABAergic interneurons (Koós and Tepper, 1999; Fig. 2*A*). Tonic striatal ACh is able

to promote dopamine release through β 2-subunitcontaining (β 2*)-nAChR receptors in VTA terminals (Rice and Cragg, 2004). Using different KO strains, Champtiaux and colleagues proposed that a combination of α 6 β 2* and α 4 β 2* nAChRs mediate the endogenous cholinergic modulation of dopamine release at the terminal level (Champtiaux et al., 2003). Considering this, we injected DH β E (0.7 μ g; dosage validated; Löf et al., 2007), an antagonist of α 4 subunit of nAChR, in the NAc before performing the PR test. By blocking α 4 receptors, we are abolishing at least 50% of dopamine release in the NAc (Champtiaux et al., 2003).

Treatment using α 4 antagonist had a significant effect on behavioral performance ($F_{(1,13)} = 43.0$, p < 0.000, two-way ANOVA; Fig. 2*E*). No effect in the breakpoint of control animals was found, yet, this treatment abolished the enhancement of breakpoint induced by D2-MSN stimulation (20.8% decrease; p < 0.000, two-way ANOVA *post hoc*). No effect on the number of pellets earned during the session was found (Extended Data Fig. 2-2).

These results suggest that cholinergic activation of VTA terminals is required for the observed behavioral effect of D2-MSN stimulation.

Enhancement of motivation by D2-MSN activation requires dopamine signaling through D1R and D2R

Activating $\alpha 6\beta 2^*$ and/or $\alpha 4\beta 2^*$ nAChRs in VTA terminals greatly enhances dopamine release in the NAc (Wonnacott et al., 2000; Cachope et al., 2012), and our previous results suggested that cholinergic modulation of VTA terminals was necessary for the observed motivation enhancement induced by D2-MSN optogenetic activation. Thus, we next tried to clarify the role of NAc dopamine receptors D1R and D2R in this process. To do so, we injected in the NAc before performance of PR test with optogenetic stimulation of D2-MSNs, R(+)-SCH-23390 hydrochloride (0.5 μ g; D1R antagonist) or sulpiride (0.2 μ g; D2R antagonist) in doses that were previously shown to have a behavioral effect (Vezina et al., 1994).

Both D1R and D2R antagonist treatment had a significant effect (two-way ANOVA; D1R antag: $F_{(1,13)} = 65.7$, p < 0.000; D2R antag: $F_{(1,13)} = 56.8$, p < 0.000; Fig. 2*F*,*G*). Interestingly, both antagonists caused a reduction in the breakpoint of control D2-eYFP animals (D1R antagonist: 25.1% decrease, p = 0.047, two-way ANOVA *post hoc*; D2R antagonist: 26.2% decrease, p = 0.013, two-way ANOVA *post hoc*).

Additionally, pharmacological inhibition of either D1R or D2R abolished the increase in motivation induced by D2-MSN optogenetic activation (D2-ChR2 vehicle vs D2-

Α











	Breakpoint effect		
	D2-eYFP	D2-ChR2	
GABA _A antagonist (bicuculline, 75ng)	=	=	
GABA _B antagonist (GCP-55845, 44ng)	=	additional ↑↑	
AchR antagonism			
(scopolamine, 25μg +	=	blocks stim. effect	
mecamylamine, 22.5μg)			
mAchR antagonist	-	=	
(scopolamine, 25µg)	-		
nAchR antagonist	-	blocks stim offect	
(mecamylamine, 22.5µg)	_	DIOCKS SUITI. ETIECI	
α 4-nAchR antagonist (DhβE, 0.7μg)	=	blocks stim. effect	
D1R antagonist		blocks stim effect	
(SCH-23390, 0.5µg)	**	bioona atim. eneor	
D2R antagonist	11	blocks stim, effect	
(sulpiride, 0.2µg)	* *		

Figure 2. Effects of different antagonists in motivation. A, Simplified schematic representation of NAc microcircuit. Left, The NAc

continued

receives cortical (prefrontal cortex (PFC)) glutamatergic inputs and VTA dopaminergic inputs. NAc D1- and D2-MSNs send GABAergic projections to VP, which in turn projects back to the NAc (not represented) and to VTA (among other regions). Besides MSNs, the NAc contains CINs and GABAergic interneurons of different natures, including FSIs, which tightly regulate striatal activity. Right, Expression of different neurotransmitter receptors in striatal neurons and terminals. Of relevance to mention that CINs also express dopamine receptor D2R and can stimulate dopamine release from VTA terminals mainly in a $\alpha 4\beta 2*nAchR$ - or $\alpha 6\beta 2*nAchR$ dependent manner. Activation of D2R autoreceptors located in VTA terminals also controls dopamine release. iGluR: ionotropic glutamate receptors; mGluR: metabotropic glutamate receptors; nAchR: nicotinic (ionotropic) cholinergic receptors; M1/M4: muscarinic (metabotropic) cholinergic receptors. B-G, Effects of different receptor antagonists in behavior. Rats were injected in the NAc with a specific antagonist immediately before the PR test with D2-MSNs optogenetic activation. B, GABA_A receptor antagonist did not alter breakpoint of control D2-eYFP animals, nor of D2-ChR2-stimulated animals. C, GABA_B receptor antagonist did not alter breakpoint of control animals, but it further increased the breakpoint of D2-ChR2-stimulated animals. **D**, Injection of mAChR + nAChR antagonist combination abolished the increased breakpoint of D2-ChR2-stimulated animals. This effect is mediated mainly by nAChR since mecamylamine per se normalized breakpoint. E, Local administration of α 4-nAChR antagonist blocked the effect of D2-MSNs optogenetic activation. F, D1R antagonist decreases the breakpoint of control D2-eYFP animals. In addition, the breakpoint enhancement induced by optogenetic activation of D2-MSNs was completely abolished by this treatment. G, D2R antagonist originated a similar effect as D1R antagonist. H, Summary of the effects of different antagonists in the breakpoint of stimulated D2-eYFP and D2-ChR2 animals (n_{D2-eYFP} = 7; n_{D2-ChR2} = 8). Error bars denote SEM; *p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.001 and refers to the comparison D2-eYFP treated versus D2-ChR2 treated (Extended Data Figs. 2-1, 2-2).

ChR2 D1R antag: p < 0.000, two-way ANOVA post hoc; D2-ChR2 vehicle vs D2-ChR2 D2R antag: p < 0.000, two-way ANOVA post hoc). A reduction in the number of pellets consumed in D1R-treated D2-eYFP rats was found (p = 0.0164, two-way ANOVA post hoc; Extended Data Fig. 2-2). No significant differences in the number of pellets consumed were found in other groups.

These results suggest that the motivation improvement is dependent on both types of dopamine receptor signaling in the NAc.

Optogenetic stimulation of NAc D2-MSNs recruits the VP and the VTA

The preceding results suggested a dopamine-dependent effect of D2-MSN optogenetic activation in motivation (summarized in Fig. 2*H*). D2-MSNs do not directly project to VTA but indirectly modulate VTA dopaminergic activity through the VP (Wu et al., 1996; Floresco et al., 2003; Grace et al., 2007; Hjelmstad et al., 2013; Kupchik et al., 2015). So, we next examined the pattern of expression of c-fos, an immediate early gene used as a marker of neuronal recruitment, after the PR test in the NAc and connected regions.

Stimulated D2-ChR2 rats showed a significant increase in c-fos staining in NAc D2R-expressing neurons, when compared with stimulated control D2-eYFP rats ($t_{(13)}$ = 12.0, p < 0.000, unpaired *t* test; Fig. 3*A*,*B*; Extended Data Fig. 3-1), and when compared with the nonstimulated side ($t_{(7)} = 7.4$, p = 0.0002, paired *t* test). This increase in c-fos expression was also observed in NAc D1R-expressing neurons when comparing D2-ChR2 with D2-eYFP rats ($t_{(13)} = 3.7$, p = 0.0028, unpaired *t* test; Fig. 3*A*,*C*), and with the contralateral nonstimulated side ($t_{(7)} = 5.3$, p =0.0011, paired *t* test).

ChAT-expressing neurons also presented increased c-fos expression when comparing D2-ChR2 with D2-eYFP rats ($t_{(13)} = 5.7$, p < 0.000, unpaired *t* test; Fig. 3*A*,*D*), or comparing with contralateral nonstimulated side ($t_{(7)} = 4.0$, p = 0.0053, paired *t* test).

In addition, we evaluated the number of c-fos⁺ cells in accumbal downstream regions: the VTA, which is innervated solely by NAc D1-MSNs (Bocklisch et al., 2013); the VP, which is directly innervated by NAc D1- and D2-MSNs (Creed et al., 2016); and the substantia nigra pars compacta (SNc) as a control region, since it is mainly innervated by dorsal striatum MSNs (Gerfen, 1984).

A significant increase in VTA c-fos⁺ cells was observed in D2-ChR2 rats in comparison to D2-eYFP-stimulated rats ($t_{(13)} = 5.3$, p < 0.000, unpaired t test; Fig. 3*E*,*F*), or when comparing with contralateral side ($t_{(7)} = 4.6$, p =0.0024, paired t test); from these, around 30% were dopaminergic neurons ($t_{(13)} = 7.1$, p < 0.000, unpaired ttest). A similar increase in c-fos was observed in the VP of D2-ChR2 in comparison with D2-eYFP rats ($t_{(13)} = 2.3$, p = 0.039, unpaired t test; Fig. 3*H*,*I*). However, no significant difference in c-fos was found between stimulated and contralateral VP in D2-ChR2 rats ($t_{(7)} = 1.2$, p =0.258, paired t test). D2-MSNs accumbal stimulation did not alter c-fos expression in the SN (Fig. 3*G*).

Optogenetic activation of NAc-VP terminals recapitulates motivation enhancement

Next, we analyzed the activity of the VP and VTA during D2-MSN optogenetic stimulation using *in vivo* single-cell electrophysiology (Fig. 4A).

Concordant with a GABAergic input, NAc D2-MSN stimulation elicited an overall reduction in the firing rate of the VP ($F_{(2,87)} = 10.6$, p < 0.000, one-way ANOVA; Fig. 4*B*), with an average spike latency of 5.7 ms (Extended Data Fig. 4-1*A*), consistent with the expected monosynaptic input from the NAc to VP. More than 90% of recorded neurons in the VP decreased their activity during stimulation, which normalized thereafter (Fig. 4*C*,*D*).

Conversely, in the VTA, we found a significant increase in global firing rate of putative VTA dopaminergic neurons (pDAergic; $F_{(2,56)} = 17.6$, p < 0.000, one-way ANOVA; Fig. 4*E*), with an average spike latency of 170 ms (Extended Data Fig. 4-1*A*), indicative of polysynaptic modulation. Of



Figure 3. Effect of optogenetic activation of D2-MSNs in the NAc and downstream targets. *A*, Representative immunostaining c-fos and D2R, D1R, or ChAT in the NAc. Scale bar: 80 μ m (n_{D2-ChR2} = 8; n_{D2-eYFP} = 7). *B*, Counting of D2R⁺ and c-fos⁺ cells in the NAc. D2-MSNs stimulation recruits more D2⁺ neurons in comparison to nonstimulated side (contralateral). Stimulated D2-ChR2 animals present increased number of D2⁺/c-fos⁺ neurons in comparison to stimulated D2-eYFP animals (control group). *C*, Counting of D1R⁺ and c-fos⁺ cells in the NAc, showing an increase in D1⁺/c-fos⁺ in stimulated versus contralateral side (or vs D2-eYFP-stimulated animals). *D*, Counting of ChAT⁺ and c-fos⁺ cells in the NAc, showing an increase in ChAT⁺/c-fos⁺ in stimulated versus contralateral side (or vs D2-eYFP-stimulated animals. *E*, Representative immunostaining for TH and c-fos in the VTA (scale bar: 100 μ m). *F*, Respective quantification of positive cells. D2-MSN stimulation increases the number of TH⁺ neurons in the VTA. *G*, SN c-fos⁺ cells counting showing no effect of stimulation. *H*, Representative immunostaining for c-fos in the VP (scale bar: 500 μ m; scale bar in inset: 100 μ m). *I*, Stimulated D2-ChR2 animals present increased c-fos staining in the VP comparison to control D2-eYFP animals; interestingly, no significant differences were found between stimulated versus nonstimulated side. Error bars denote SEM; **p* < 0.05, ***p* < 0.01, ****p* < 0.001 (Extended Data Fig. 3-1).

these pDAergic neurons, 82.8% increased activity during stimulation (Fig. 4F,G). No significant differences were observed in the activity of pGABAergic VTA neurons, although there was a trend for decreased activity during D2-MSNs stimulation (Fig. 4E,G).

The previous data suggested an indirect modulation of VTA activity through the VP, so we decided to optogenetically stimulate D2-MSN terminals in the VP during the PR test (Fig. 4*H*-*K*). Regarding training, both groups learned in a similar manner [CRF: $F_{(1,72)} = 0.0, p = 0.856$,

two-way ANOVA (Extended Data Fig. 4-1*B*); FR: $F_{(3,24)} = 180.4$, p < 0.000, two-way ANOVA (Extended Data Fig. 4-1*C*)].

Optical stimulation (40 light pulses of 12.5 ms at 40 Hz) of D2-MSN-VP terminals elicited a significant increase in the breakpoint of ChR2-stimulated rats in comparison with control-stimulated rats (40% increase; $t_{(11)} = 10.7$, p < 0.000, unpaired *t* test; Fig. 4/). All D2-ChR2 NAc-VP rats displayed a significant increase in breakpoint in the session with optical stimulation (ON) in comparison with



Figure 4. Activation of D2-MSN terminals in the VP increases motivation. *A*, Schematic representation of the *in vivo* single-cell electrophysiological recordings with optogenetic manipulation of NAc D2-MSNs cell bodies. *B*, NAc D2-MSN optical stimulation (40 Hz, 12.5-ms pulses for 1 s) decrease net firing rate of VP neurons. *C*, 93.3% of VP cells decrease firing rate and 6.7% did not respond to stimulation (n = 30 cells/four rats). *D*, Time histogram showing the number of events in the VP before, during, and after a 40-Hz stimulus of NAc D2-MSNs. *E*, D2-MSN optical stimulation increase the net firing rate of pDAergic neurons of the VTA, with no significant changes in the net firing rate of pGABAergic neurons ($n_{pDAergic} = 29$ cells/four rats; $n_{GABAergic} = 5$ cells/four rats). *F*, 82.8% of pDAergic cells increased firing rate in response to stimulation; most of cells returned to baseline activity after the stimulus. pGABAergic neurons presented a majority of inhibitory responses to D2-MSN stimulation. *G*, Time histogram showing the number of events in the VTA before, during, and after a 40-Hz stimulus of NAc D2-MSNs. *H*, Strategy used for optogenetic stimulation of D2-MSN terminals in the VP (D2-ChR2 NAc-VP group). *I*, Optogenetic activation of D2-MSN-VP terminals during cue exposure strongly enhanced breakpoint. *J*, All animals increase breakpoint in the session with stimulation (ON) versus nonstimulation session (OFF). *K*, Number of pellets consumed in the PR session was similar between groups. ($n_{D2-eYFP}$ NAc-VP = 6; $n_{D2-ChR2}$ NAc-VP = 8). Error bars denote SEM; ***p < 0.001 (Extended Data Fig. 4-1).

the OFF session ($t_{(6)} = 10.2$, p < 0.000, paired *t* test; Fig. 4*J*). No differences in the number of food pellets earned during the PR session were found ($t_{(12)} = 1.7$, p = 0.112, unpaired *t* test; Fig. 4*K*).

Discussion

Local microcircuits in combination with excitatory and inhibitory inputs from upstream regions play an important role in striatal function. Here, we show that activation of



Figure 5. Proposed model for D2-MSNs optogenetic activation effects in NAc microcircuit. NAc D2-MSNs send GABAergic projections to VP neurons, which in turn provide a tonic inhibitory input to the VTA (1). Optogenetic activation of D2-MSNs reduces VP net activity (2), reducing VP-to-VTA inhibitory tone (3). This triggers an increase in VTA dopaminergic activity (4). These VTA dopaminergic signals require D1R and D2R signaling in the NAc (5', 5). Interestingly, cholinergic-dependent control of VTA dopaminergic terminals in the NAc (via α 4-nAChR) is essential for this process (6). (7) Optical stimulation can also be activating D2-expressing CINs that strongly influence dopamine release and shape behavior.

D2-MSNs during cue exposure increases willingness to work in the PR test, and that a concerted action of different neurotransmitter systems in the striatum is required for this behavioral effect (Fig. 5).

We first evaluated the impact of GABAergic transmission since GABAergic MSNs highly synapse within each other in the NAc (Sesack and Pickel, 1990; Dobbs et al., 2016), providing a weak lateral inhibitory network (feedback inhibition; Tepper et al., 2008). This MSN-MSN reciprocal regulation mainly occurs in a GABA_A receptor mediated manner (Tunstall et al., 2002). Our results suggest that the D2-MSN-driven enhancement in motivation is not dependent on GABAergic signaling, since neither GABA_A nor GABA_B antagonists normalized the phenotype. However, we do observe an additional increase in the breakpoint of both control and D2-MSN-stimulated animals on GABA_B antagonist administration in the NAc. Such finding is likely to rely on enhanced corticostriatal glutamatergic release on the blockade of presynaptic GABAB receptors. In fact, MSNs express GABA_B receptors, application of exogenous GABA_B agonists does not lead to any MSN electrophysiological effect (Logie et al., 2013), although it significantly supresses glutamatergic inputs onto MSNs via a pre-synaptic mechanism (Nisenbaum et al., 1993; Logie et al., 2013). Apart from classic studies showing that NAc cue-evoked firing is abolished by VTA inactivation (Yun et al., 2004), there is also evidence that cue-evoked excitations of NAc core neurons depend on mPFC glutamatergic projections, and contribute to the behavioral response to reward-predictive cues (Ishikawa et al., 2008).

Yet, it is important to refer that although sparse, GABAergic interneurons (which do not express D2R; Tritsch and Sabatini, 2012) display highly branched dendritic and extensive

March/April 2018, 5(2) e0386-18.2018

axonal arborisations (Kawaguchi, 1997; Ibáñez-Sandoval et al., 2011; English et al., 2012) and are capable of exerting a powerful control over striatal excitability (feed-forward inhibition; Tepper et al., 2004, 2008). They also express GABA_B receptors (Logie et al., 2013), so the blockage of this specific feed-forward inhibition might also contribute for the observed increase in motivational drive.

In addition to local GABA control, the striatum also contains CINs, which have both excitatory and inhibitory effects in striatal MSNs (Sullivan and Brake, 2003; Pakhotin and Bracci, 2007; Witten et al., 2010). In primates, CINs exhibit multiphasic responses to motivationally salient stimuli that mirror those of midbrain dopamine neurons, being important for reward-related learning (Kitabatake et al., 2003; Joshua et al., 2008; Witten et al., 2010; Cachope et al., 2012). Since 80% of CINs express D2R (Alcantara et al., 2003), one can argue that our optogenetic stimulation protocol directly activates these interneurons, enhancing ACh release in the striatum. In line with this, we found an increase in ChAT⁺/c-fos⁺ neurons in stimulated animals.

In vivo selective activation of CINs is sufficient to elicit dopamine release directly in the NAc and independently of the soma, by activation of nAChRs in VTA terminals (Cachope et al., 2012; Threlfell et al., 2012). It has been suggested that these nAChR act as dynamic detectors of ACh concentrations, enhancing the contrast between tonic and burst dopaminergic firing (Brunzell et al., 2010). In an elegant study using different KO strains, Champtiaux and colleagues proposed that a combination of $\alpha 6\beta 2*$ and $\alpha 4\beta 2*$ nAChRs mediate endogenous cholinergic modulation of dopamine release at the VTA terminal level (Champtiaux et al., 2003). Here, we show that $\alpha 4$ antag-

onist, DH β E, blocks D2-MSN-dependent increase in motivation, suggesting that ACh-mediated dopamine release from VTA terminals is crucial for the observed behavioral effect. It is important to refer that besides CINs, the NAc may also receive cholinergic inputs from the laterodorsal tegmentum (Dautan et al., 2014), although the function of these projections remains completely unknown.

In the NAc, α 4 nAChRs subunits are expressed mainly in VTA dopaminergic terminals but also in some GABAergic FSIs. So, the observed dampening of motivation with α 4 antagonist could also depend on these interneurons. However, our data does not support this because GABA receptor antagonists did not abolish the optogenetic-induced behavioral effect.

In addition to local cholinergic control, our data suggests an indirect effect in VTA dopaminergic activity through the VP. First, c-fos analysis revealed increased recruitment of both VP and VTA regions. VP data are somehow surprising considering the GABAergic nature of accumbal-VP monosynaptic projections (Root et al., 2010; Kupchik et al., 2015). Although most studies associate c-fos expression with increased neuronal activity, at least one study has shown that activating striatal MSNs increases c-fos in the VP (Page and Everitt, 1993). Yet, rather than directly associate D2-MSN activation with this increase in c-fos in the VP, we just aim to illustrate that the VP is being differently recruited in stimulated animals. In fact, animals were killed 90 min after the beginning of the PR test, so c-fos reactivity is a sum of all neuronal events that occur during the test, and do not reflect only the optogenetic activation period.

D2-MSN stimulation decreased VP firing rate, and indirectly increased VTA dopaminergic activity, with less effects in GABAergic VTA neurons, consistent with the preferential innervation of VTA dopaminergic neurons by VP inputs (Mahler et al., 2014). So, our hypothesis is that D2-MSNs reduce the tonic VP-VTA inhibitory input, contributing for enhanced dopaminergic activity, which is known to boost motivational drive (Peciña et al., 2003; Cagniard et al., 2006). In fact, it was shown that inhibition of NAc afferents to the VP or direct infusion of GABAergic agonists into the VP, selectively increased the population activity of dopamine neurons, rising NAc dopamine efflux (Floresco et al., 2003). In line with this, we showed that optogenetic activation of D2-MSN terminals in the VP was sufficient to increase motivation. These findings are in agreement with the emerging notion that the VP is crucial for reward and motivation toward natural rewards and drugs of abuse. In fact, different subregions of the VP mediate different aspects of rewarded behavior, from motivation/incentive salience to reward prediction and consumption (Smith et al., 2009; Root et al., 2015). Yet, it is important to refer that VP is not only a relay area for indirect NAc inputs, since VP neuron responses can occur at a shorter latency than cue-elicited responses in NAc neurons (Richard et al., 2016), and that VP firing rate reflects the strength of incentive motivation (Ahrens et al., 2016).

The increased dopaminergic signals arising from the VTA act mainly (not exclusively since some interneurons also express dopamine receptors) on MSNs either by

activating D1R or D2R. Local administration of either D1R or D2R antagonists decreases motivation in control animals, and also abolished D2-MSN-induced positive effects in motivation, indicating a synergistic effect of both MSN populations. In this perspective, it is important to refer that blockade of D2R would be expected to enhance activity of D2-MSNs since D2Rs are coupled to inhibitory G-proteins (Beaulieu and Gainetdinov, 2011). Yet, one has to bear in mind that D2R antagonists can also act in D2 auto-receptors in VTA terminals, disinhibiting presynaptic control of dopamine release (Anzalone et al., 2012).

Interestingly, D2-MSN optogenetic activation during cue exposure also indirectly recruited D1-MSNs, as assessed by an increase in the number of D1⁺/c-fos⁺ cells in the NAc on stimulation. Considering the proposed role for D1R-expressing neurons in reinforcement (Lobo et al., 2010; Kravitz et al., 2012), this activation probably also contributes for the behavioral output.

In summary, we show that NAc D2-MSN optogenetic activation enhances motivation through enhanced VTAdriven dopaminergic signaling. The behavioral effect was dependent on both D1R and D2R signaling in the NAc, suggesting that a coordinated action between these two striatal populations is needed to increase motivational levels.

References

- Ahrens AM, Meyer PJ, Ferguson LM, Robinson TE, Aldridge JW (2016) Neural activity in the ventral pallidum encodes variation in the incentive value of a reward cue. J Neurosci 36:7957–7970. CrossRef
- Alcantara AA, Chen V, Herring BE, Mendenhall JM, Berlanga ML (2003) Localization of dopamine D2 receptors on cholinergic interneurons of the dorsal striatum and nucleus accumbens of the rat. Brain Res 986:22–29. Medline
- Anzalone A, Lizardi-Ortiz JE, Ramos M, De Mei C, Hopf FW, laccarino C, Halbout B, Jacobsen J, Kinoshita C, Welter M, Caron MG, Bonci A, Sulzer D, Borrelli E (2012) Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J Neurosci 32:9023–9034. CrossRef Medline
- Bailey MR, Simpson EH, Balsam PD (2016) Neural substrates underlying effort, time, and risk-based decision making in motivated behavior. Neurobiol Learn Mem 133:233–256. CrossRef Medline
- Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, Mukhopadhyay D (2004) Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 64:5551–5555. CrossRef Medline
- Beaulieu J-M, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182– 217. CrossRef Medline
- Bocklisch C, Pascoli V, Wong JCY, House DRC, Yvon C, de Roo M, Tan KR, Lüscher C (2013) Cocaine disinhibits dopamine neurons by potentiation of GABA transmission in the ventral tegmental area. Science 341:1521–1525. CrossRef
- Brunzell DH, Boschen KE, Hendrick ES, Beardsley PM, McIntosh JM (2010) Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine. Neuropsychopharmacology 35:665–673. CrossRef Medline
- Cachope R, Mateo Y, Mathur BN, Irving J, Wang H-L, Morales M, Lovinger DM, Cheer JF (2012) Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing. Cell Rep 2:33–41. CrossRef Medline

Cagniard B, Balsam PD, Brunner D, Zhuang X (2006) Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 31: 1362–1370. CrossRef Medline

Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Léna C, Clementi F, Moretti M, Rossi FM, Le Novère N, McIntosh JM, Gardier AM, Changeux J-P (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 23:7820–7829. CrossRef

- Creed M, Ntamati NR, Chandra R, Lobo MK, Lüscher C (2016) Convergence of reinforcing and anhedonic cocaine effects in the ventral pallidum. Neuron 92:214–226. CrossRef Medline
- Dautan D, Huerta-Ocampo I, Witten IB, Deisseroth K, Bolam JP, Gerdjikov T, Mena-Segovia J (2014) A major external source of cholinergic innervation of the striatum and nucleus accumbens originates in the brainstem. J Neurosci 34:4509–4518. CrossRef
- Dobbs LK, Kaplan AR, Lemos JC, Matsui A, Rubinstein M, Alvarez VA (2016) Dopamine regulation of lateral inhibition between striatal neurons gates the stimulant actions of cocaine. Neuron 90:1100–1113. CrossRef Medline

English DF, Ibanez-Sandoval O, Stark E, Tecuapetla F, Buzsáki G, Deisseroth K, Tepper JM, Koos T (2012) GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons. Nat Neurosci 15:123–130. CrossRef

Floresco SB, West AR, Ash B, Moore H, Grace AA (2003) Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6:968–973. CrossRef Medline

Gerfen CR (1984) The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 311: 461–464. Medline

- Giorgetti M, Hotsenpiller G, Froestl W, Wolf ME (2002) *In vivo* modulation of ventral tegmental area dopamine and glutamate efflux by local GABAB receptors is altered after repeated amphetamine treatment. Neuroscience 109:585–595. CrossRef
- Grace AA, Floresco SB, Goto Y, Lodge DJ (2007) Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30:220–227. CrossRef Medline
- Haber SN (2003) The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 26:317–330. Medline
- Hill JA, Zoli M, Bourgeois JP, Changeux JP (1993) Immunocytochemical localization of a neuronal nicotinic receptor: the beta 2-subunit. J Neurosci 13:1551–1568. Medline
- Hjelmstad GO, Xia Y, Margolis EB, Fields HL (2013) Opioid modulation of ventral pallidal afferents to ventral tegmental area neurons. J Neurosci 33:6454–6459. CrossRef Medline
- Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29:565–598. CrossRef Medline
- Ibáñez-Sandoval O, Tecuapetla F, Unal B, Shah F, Koós T, Tepper JM (2010) Electrophysiological and morphological characteristics and synaptic connectivity of tyrosine hydroxylase-expressing neurons in adult mouse striatum. J Neurosci 30:6999–7016. CrossRef
- Ibáñez-Sandoval O, Tecuapetla F, Unal B, Shah F, Koós T, Tepper JM (2011) A novel functionally distinct subtype of striatal neuropeptide Y interneuron. J Neurosci 31:16757–16769. CrossRef

Ibáñez-Sandoval O, Xenias HS, Tepper JM, Koós T (2015) Dopaminergic and cholinergic modulation of striatal tyrosine hydroxylase interneurons. Neuropharmacology 95:468–476. CrossRef Medline

- Ikeda H, Kotani A, Koshikawa N, Cools AR (2010) Differential role of GABAA and GABAB receptors in two distinct output stations of the rat striatum: studies on the substantia nigra pars reticulata and the globus pallidus. Neuroscience 167:31–39. CrossRef Medline
- Ishikawa A, Ambroggi F, Nicola SM, Fields HL (2008) Dorsomedial prefrontal cortex contribution to behavioral and nucleus accumbens neuronal responses to incentive cues. J Neurosci 28:5088– 5098. CrossRef Medline
- Jin X, Tecuapetla F, Costa RM (2014) Basal ganglia subcircuits distinctively encode the parsing and concatenation of action sequences. Nat Neurosci 17:423–430. CrossRef Medline

- Jones IW, Wonnacott S (2004) Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci 24:11244–11252. CrossRef Medline
- Jones IW, Bolam JP, Wonnacott S (2001) Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones. J Comp Neur 439: 235–247. Medline
- Joshua M, Adler A, Mitelman R, Vaadia E, Bergman H (2008) Midbrain dopaminergic neurons and striatal cholinergic interneurons encode the difference between reward and aversive events at different epochs of probabilistic classical conditioning trials. J Neurosci 28:11673–11684. CrossRef
- Kandov Y, Israel Y, Kest A, Dostova I, Verasammy J, Bernal SY, Kasselman L, Bodnar RJ (2006) GABA receptor subtype antagonists in the nucleus accumbens shell and ventral tegmental area differentially alter feeding responses induced by deprivation, glucoprivation and lipoprivation in rats. Brain Res 1082:86–97. Cross-Ref Medline
- Kawaguchi Y (1997) Neostriatal cell subtypes and their functional roles. Neurosci Res 27:1–8. Medline
- Kelley AE, Berridge KC (2002) The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22:3306–3311. Medline Medline
- Kitabatake Y, Hikida T, Watanabe D, Pastan I, Nakanishi S (2003) Impairment of reward-related learning by cholinergic cell ablation in the striatum. Proc Natl Acad Sci USA 100:7965–7970.
- Koós T, Tepper JM (1999) Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 2:467–472. CrossRef Medline
- Kravitz AV, Tye LD, Kreitzer AC (2012) Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nat Neurosci 15:816–818. CrossRef Medline
- Kupchik YM, Brown RM, Heinsbroek JA, Lobo MK, Schwartz DJ, Kalivas PW (2015) Coding the direct/indirect pathways by D1 and D2 receptors is not valid for accumbens projections. Nat Neurosci 18:1230–1232.
- Lim SAO, Kang UJ, McGehee DS (2014) Striatal cholinergic interneuron regulation and circuit effects. Front Synaptic Neurosci 6:22. CrossRef
- Lobo MK, Covington HE, Chaudhury D, Friedman AK, Sun H, Damez-Werno D, Dietz DM, Zaman S, Koo JW, Kennedy PJ, Mouzon E, Mogri M, Neve RL, Deisseroth K, Han M-H, Nestler EJ (2010) Cell type–specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 330:385–390. CrossRef Medline
- Löf E, Olausson P, deBejczy A, Stomberg R, McIntosh JM, Taylor JR, Söderpalm B (2007) Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. Psychopharmacology (Berl) 195:333– 343. CrossRef Medline
- Logie C, Bagetta V, Bracci E (2013) Presynaptic control of corticostriatal synapses by endogenous GABA. J Neurosci 33:15425– 15431. CrossRef Medline
- Lu XY, Ghasemzadeh MB, Kalivas PW (1998) Expression of D1 receptor, D2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the nucleus accumbens. Neuroscience 82:767–780. Medline
- Luedtke RR, Griffin SA, Conroy SS, Jin X, Pinto A, Sesack SR (1999) Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes. J Neuroimmunol 101:170–187. Medline
- Luessen DJ, Hinshaw TP, Sun H, Howlett AC, Marrs G, McCool BA, Chen R (2016) RGS2 modulates the activity and internalization of dopamine D2 receptors in neuroblastoma N2A cells. Neuropharmacology 110:297–307. CrossRef Medline
- Mahler SV, Vazey EM, Beckley JT, Keistler CR, McGlinchey EM, Kaufling J, Wilson SP, Deisseroth K, Woodward JJ, Aston-Jones G (2014) Designer receptors show role for ventral pallidum input to

ventral tegmental area in cocaine seeking. Nat Neurosci 17:577–585. CrossRef Medline

- Nadal R, Armario A, Janak P (2002) Positive relationship between activity in a novel environment and operant ethanol selfadministration in rats. Psychopharmacology (Berl) 162:333–338. CrossRef
- Natsubori A, Tsutsui-Kimura I, Nishida H, Bouchekioua Y, Sekiya H, Uchigashima M, Watanabe M, de Kerchove d'Exaerde A, Mimura M, Takata N, Tanaka KF (2017) Ventrolateral striatal medium spiny neurons positively regulate food-incentive, goal-directed behavior independently of D1 and D2 selectivity. J Neurosci 37:2723–2733. CrossRef
- Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Illgen-Wilcke B; FELASA (Federation of European Laboratory Animal Science Associations Working Group on Health Monitoring of Rodent and Rabbit Colonies) (2002) Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 36:20–42. CrossRef
- Nisenbaum ES, Berger TW, Grace AA (1993) Depression of glutamatergic and GABAergic synaptic responses in striatal spiny neurons by stimulation of presynaptic GABAB receptors. Synapse 14:221– 242. [CrossRef][CrossRef
- Page KJ, Everitt BJ (1993) Transsynaptic induction of c-fos in basal forebrain, diencephalic and midbrain neurons following AMPA-induced activation of the dorsal and ventral striatum. Exp Brain Res 93:399–411. Medline
- Pakhotin P, Bracci E (2007) Cholinergic interneurons control the excitatory input to the striatum. J Neurosci 27:391–400. CrossRef Medline
- Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates. San Diego: Elsevier Academic Press.
- Peciña S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X (2003) Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci 23:9395–9402. CrossRef
- Perry ML, Pratt WE, Baldo BA (2014) Overlapping striatal sites mediate scopolamine-induced feeding suppression and muopioid-mediated hyperphagia in the rat. Psychopharmacology (Berl) 231:919–928. CrossRef Medline
- Rahman S, McBride WJ (2002) Involvement of GABA and cholinergic receptors in the nucleus accumbens on feedback control of somatodendritic dopamine release in the ventral tegmental area. J Neurochem 80:646–654. Medline
- Rice ME, Cragg SJ (2004) Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 7:583–584. CrossRef Medline
- Richard JM, Ambroggi F, Janak PH, Fields HL (2016) Ventral pallidum neurons encode incentive value and promote cue-elicited instrumental actions. Neuron 90:1165–1173. CrossRef Medline
- Root DH, Fabbricatore AT, Ma S, Barker DJ, West MO (2010) Rapid phasic activity of ventral pallidal neurons during cocaine selfadministration. Synapse 64:704–713.
- Root DH, Melendez RI, Zaborszky L, Napier TC (2015) The ventral pallidum: subregion-specific functional anatomy and roles in motivated behaviors. Prog Neurobiol 130:29–70. CrossRef Medline
- Sesack SR, Pickel VM (1990) In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res 527:266– 279. Medline
- Smith KS, Tindell AJ, Aldridge JW, Berridge KC (2009) Ventral pallidum roles in reward and motivation. Behav Brain Res 196:155– 167. CrossRef Medline
- Soares-Cunha C, Coimbra B, David-Pereira A, Borges S, Pinto L, Costa P, Sousa N, Rodrigues AJ (2016a) Activation of D2 dopamine receptor-expressing neurons in the nucleus accumbens increases motivation. Nat Commun 7:11829. CrossRef
- Soares-Cunha C, Coimbra B, Sousa N, Rodrigues AJ (2016b) Reappraising striatal D1- and D2-neurons in reward and aversion. Neurosci Biobehav Rev 68:370–386. CrossRef
- Sullivan RM, Brake WG (2003) What the rodent prefrontal cortex can teach us about attention-deficit/hyperactivity disorder: the critical

role of early developmental events on prefrontal function. Behav Brain Res 146:43–55. Medline

- Tepper JM, Bolam JP (2004) Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol 14:685–692. Cross-Ref Medline
- Tepper JM, Koós T, Wilson CJ (2004) GABAergic microcircuits in the neostriatum. Trends Neurosci 27:662–669. CrossRef Medline
- Tepper JM, Wilson CJ, Koós T (2008) Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res Rev 58:272–281. CrossRef Medline
- Threlfell S, Lalic T, Platt NJ, Jennings KA, Deisseroth K, Cragg SJ (2012) Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 75:58–64. CrossRef Medline
- Totah NKB, Kim Y, Moghaddam B (2013) Distinct prestimulus and poststimulus activation of VTA neurons correlates with stimulus detection. J Neurophysiol 110:75–85. CrossRef
- Tritsch NX, Sabatini BL (2012) Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron 76:33–50. CrossRef Medline
- Tunstall MJ, Oorschot DE, Kean A, Wickens JR (2002) Inhibitory interactions between spiny projection neurons in the rat striatum. J Neurophysiol 88:1263–1269. CrossRef Medline
- Ungless MA, Grace AA (2012) Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci 35:422–430. CrossRef Medline
- Ungless MA, Magill PJ, Bolam JP (2004) Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 303:2040–2042. CrossRef Medline
- Vezina P, Blanc G, Glowinski J, Tassin JP (1994) Blockade of D-1 dopamine receptors in the medial prefrontal cortex produces delayed effects on pre- and postsynaptic indices of dopamine function in the nucleus accumbens. Synapse 16:104–112. CrossRef
- Vicente AM, Galvão-Ferreira P, Tecuapetla F, Costa RM (2016) Direct and indirect dorsolateral striatum pathways reinforce different action strategies. Curr Biol 26:R267–R269. CrossRef Medline
- Wise RA (1998) Drug-activation of brain reward pathways. Drug Alcohol Depend 51:13–22. Medline
- Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5:483–494. CrossRef Medline
- Witten IB, Lin S-C, Brodsky M, Prakash R, Diester I, Anikeeva P, Gradinaru V, Ramakrishnan C, Deisseroth K (2010) Cholinergic interneurons control local circuit activity and cocaine conditioning. Science 330:1677–1681. CrossRef Medline
- Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW (2000) Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur J Pharmacol 393:51–58. Medline
- Wu M, Hrycyshyn AW, Brudzynski SM (1996) Subpallidal outputs to the nucleus accumbens and the ventral tegmental area: anatomical and electrophysiological studies. Brain Res 740:151–161. Medline
- Yan Z, Flores-Hernandez J, Surmeier DJ (2001) Coordinated expression of muscarinic receptor messenger RNAs in striatal medium spiny neurons. Neuroscience 103:1017–1024. Medline
- Yee J, Famous KR, Hopkins TJ, McMullen MC, Pierce RC, Schmidt HD (2011) Muscarinic acetylcholine receptors in the nucleus accumbens core and shell contribute to cocaine priming-induced reinstatement of drug seeking. Eur J Pharmacol 650:596–604. CrossRef Medline
- Yun IA, Wakabayashi KT, Fields HL, Nicola SM (2004) The ventral tegmental area is required for the behavioral and nucleus accumbens neuronal firing responses to incentive cues. J Neurosci 24: 2923–2933. CrossRef Medline
- Zalocusky KA, Ramakrishnan C, Lerner TN, Davidson TJ, Knutson B, Deisseroth K (2016) Nucleus accumbens D2R cells signal prior outcomes and control risky decision-making. Nature 531:642–646. CrossRef Medline
- Zhou L, Furuta T, Kaneko T (2003) Chemical organization of projection neurons in the rat accumbens nucleus and olfactory tubercle. Neuroscience 120:783–798. Medline